{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:15:17Z","timestamp":1790792117379,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006954","name":"Tufts Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["HO-18-19056\/ VxHO-000052"],"award-info":[{"award-number":["HO-18-19056\/ VxHO-000052"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.japh.2021.11.010","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T02:03:49Z","timestamp":1636682629000},"page":"526-536.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5319-9493","authenticated-orcid":false,"given":"Brandon J.","family":"Patterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7065-9607","authenticated-orcid":false,"given":"Chi-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5367-6472","authenticated-orcid":false,"given":"Catherine B.","family":"McGuiness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7269-2884","authenticated-orcid":false,"given":"Siyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9863-7098","authenticated-orcid":false,"given":"Lisa I.","family":"Glasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-7512","authenticated-orcid":false,"given":"Kainan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-3669","authenticated-orcid":false,"given":"Philip O.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.japh.2021.11.010_bib1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ncl.2008.03.011","article-title":"Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency","volume":"26","author":"Mueller","year":"2008","journal-title":"Neurol Clin"},{"issue":"3","key":"10.1016\/j.japh.2021.11.010_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.japh.2021.11.010_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s13671-011-0004-4","article-title":"The epidemiology and prevention of herpes zoster","volume":"1","author":"Forbes","year":"2012","journal-title":"Curr Dermatol Rep"},{"key":"10.1016\/j.japh.2021.11.010_bib4","first-page":"341","article-title":"VZV T cell-mediated immunity","volume":"342","author":"Weinberg","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.japh.2021.11.010_bib5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1186\/s12879-020-05648-6","article-title":"Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009\u20132014","volume":"20","author":"Mu\u00f1oz-Quiles","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.japh.2021.11.010_bib6","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/cid\/ciz1090","article-title":"Herpes zoster risk in immunocompromised adults in the United States: a systematic review","volume":"71","author":"McKay","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.japh.2021.11.010_bib7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/1471-2334-14-402","article-title":"Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study","volume":"14","author":"Gater","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.japh.2021.11.010_bib8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.japh.2021.11.010_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality-of-life","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.japh.2021.11.010_bib12","unstructured":"SHINGRIX (Zoster Vaccine Recombinant A. Prescribing. Inf Res, (Triangle, Park, NC). GlaxoSmithKline;27709."},{"issue":"11","key":"10.1016\/j.japh.2021.11.010_bib13","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.japh.2021.11.010_bib14","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.japh.2021.11.010_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","article-title":"Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study","volume":"36","author":"Lal","year":"2018","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.japh.2021.11.010_bib16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant Zoster Vaccine (Shingrix): real-world effectiveness in the first two years post-licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6 Suppl 4","key":"10.1016\/j.japh.2021.11.010_bib18","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.amepre.2015.03.005","article-title":"Racial and ethnic disparities in vaccination coverage among adult populations in the U.S","volume":"49","author":"Lu","year":"2015","journal-title":"Am J Prev Med"},{"issue":"Suppl 2","key":"10.1016\/j.japh.2021.11.010_bib19","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.2105\/AJPH.2008.151332","article-title":"Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study","volume":"99","author":"Nelson","year":"2009","journal-title":"Am J Public Health"},{"issue":"1","key":"10.1016\/j.japh.2021.11.010_bib20","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.amepre.2016.08.029","article-title":"Herpes zoster vaccine coverage in older adults in the U.S., 2007\u20132013","volume":"52","author":"Zhang","year":"2017","journal-title":"Am J Prev Med"},{"issue":"22","key":"10.1016\/j.japh.2021.11.010_bib21","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A\u00a0vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.japh.2021.11.010_bib22","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1080\/21645515.2021.1879579","article-title":"Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019","volume":"17","author":"Patterson","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.japh.2021.11.010_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa005","article-title":"Risk factors for herpes zoster infection: a meta-analysis","volume":"7","author":"Marra","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.japh.2021.11.010_bib24","author":"Dooling"},{"key":"10.1016\/j.japh.2021.11.010_bib25","author":"Cubanski"},{"issue":"6","key":"10.1016\/j.japh.2021.11.010_bib26","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.vaccine.2020.12.076","article-title":"Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older","volume":"39","author":"Ackerson","year":"2021","journal-title":"Vaccine"},{"issue":"8 Spec No","key":"10.1016\/j.japh.2021.11.010_bib27","first-page":"SP286","article-title":"Impact of medical and\/or pharmacy reimbursement on adult vaccination rates","volume":"24","author":"Deshpande","year":"2018","journal-title":"Am J Manag Care"},{"issue":"12","key":"10.1016\/j.japh.2021.11.010_bib28","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1080\/21645515.2016.1215393","article-title":"Community pharmacies as sites of adult vaccination: a systematic review","volume":"12","author":"Burson","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.japh.2021.11.010_bib29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1370\/afm.1542","article-title":"Vaccinations administered during off-clinic hours at a national community pharmacy: implications for increasing patient access and convenience","volume":"11","author":"Goad","year":"2013","journal-title":"Ann Fam Med"},{"issue":"30","key":"10.1016\/j.japh.2021.11.010_bib30","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1016\/j.vaccine.2016.04.076","article-title":"A\u00a0national examination of pharmacy-based immunization statutes and their association with influenza vaccinations and preventive health","volume":"34","author":"McConeghy","year":"2016","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.japh.2021.11.010_bib31","first-page":"930","article-title":"Costs of adult vaccination in medical settings and pharmacies: an observational study","volume":"20","author":"Singhal","year":"2014","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"7","key":"10.1016\/j.japh.2021.11.010_bib32","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1532-5415.2010.02904.x","article-title":"Disparities in influenza vaccine coverage in the United States, 2008","volume":"58","author":"Linn","year":"2010","journal-title":"J\u00a0Am Geriatr Soc"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319121004714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319121004714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:49:04Z","timestamp":1761544144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319121004714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1544319121004714"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2021.11.010","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2021.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association\u00ae. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}